239 related articles for article (PubMed ID: 32440158)
1. Inhibition of Aurora Kinase A by Alisertib Reduces Cell Proliferation and Induces Apoptosis and Autophagy in HuH-6 Human Hepatoblastoma Cells.
Tan J; Xu W; Lei L; Liu H; Wang H; Cao X; Xu M
Onco Targets Ther; 2020; 13():3953-3963. PubMed ID: 32440158
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
3. Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling.
Shang YY; Yao M; Zhou ZW; Jian-Cui ; Li-Xia ; Hu RY; Yu YY; Qiong-Gao ; Biao-Yang ; Liu YX; Dang J; Zhou SF; Nan-Yu
Oncotarget; 2017 Dec; 8(63):107076-107088. PubMed ID: 29291012
[TBL] [Abstract][Full Text] [Related]
4. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Ding YH; Zhou ZW; Ha CF; Zhang XY; Pan ST; He ZX; Edelman JL; Wang D; Yang YX; Zhang X; Duan W; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():425-64. PubMed ID: 25624750
[TBL] [Abstract][Full Text] [Related]
5. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
6. Alisertib induces G
Liu Z; Wang F; Zhou ZW; Xia HC; Wang XY; Yang YX; He ZX; Sun T; Zhou SF
Am J Transl Res; 2017; 9(3):845-873. PubMed ID: 28386317
[TBL] [Abstract][Full Text] [Related]
7. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
8. Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells.
Ren BJ; Zhou ZW; Zhu DJ; Ju YL; Wu JH; Ouyang MZ; Chen XW; Zhou SF
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26729093
[TBL] [Abstract][Full Text] [Related]
9. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma.
Ding X; Huang T; Peng C; Ahn KS; Andersen JB; Lewinska M; Cao Y; Xu G; Chen G; Kong B; Friess H; Shen S; Roberts LR; Wang L; Zou X
J Cancer; 2020; 11(8):2241-2251. PubMed ID: 32127951
[No Abstract] [Full Text] [Related]
12. Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells.
Zhu Q; Yu X; Zhou ZW; Zhou C; Chen XW; Zhou SF
Curr Cancer Drug Targets; 2017; 17(4):386-401. PubMed ID: 27396604
[TBL] [Abstract][Full Text] [Related]
13. A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells.
Zhu Q; Luo M; Zhou C; Zhou Z; He Z; Yu X; Zhou S
Am J Transl Res; 2017; 9(8):3558-3572. PubMed ID: 28861148
[TBL] [Abstract][Full Text] [Related]
14. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.
Mazumdar A; Henderson YC; El-Naggar AK; Sen S; Clayman GL
Head Neck; 2009 May; 31(5):625-34. PubMed ID: 19107951
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-26-5p functions as a new inhibitor of hepatoblastoma by repressing lin-28 homolog B and aurora kinase a expression.
Zhang Y; Zhao Y; Wu J; Liangpunsakul S; Niu J; Wang L
Hepatol Commun; 2018 Jul; 2(7):861-871. PubMed ID: 30027143
[TBL] [Abstract][Full Text] [Related]
17. A SILAC-based proteomics elicits the molecular interactome of alisertib (MLN8237) in human erythroleukemia K562 cells.
Shu LP; Zhou ZW; Zi D; He ZX; Zhou SF
Am J Transl Res; 2015; 7(11):2442-61. PubMed ID: 26807190
[TBL] [Abstract][Full Text] [Related]
18. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
Wang S; Sun L
Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
[TBL] [Abstract][Full Text] [Related]
19. CDCA2 promotes melanoma progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A.
Sun W; Jin Y; Wei C; Xu Y; Liu W; Zhong J; Zou Z; Lin X; Xiang Y; Chen Y
Eur J Cancer; 2023 Jul; 188():49-63. PubMed ID: 37196484
[TBL] [Abstract][Full Text] [Related]
20. The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo.
Sak M; Williams BJ; Zumbar CT; Teer L; Al-Kawaaz MNG; Kakar A; Hey AJ; Wilson MJ; Schier LM; Chen J; Lehman NL
Cancer Chemother Pharmacol; 2023 Feb; 91(2):191-201. PubMed ID: 36694044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
